Universitätsklinikum Freiburg

Clinical trials in this area focus on cancer and blood disorders, including ALK+ non-small cell lung cancer, metastatic colorectal cancer, endometrial cancer, prostate cancer, high-risk neuroblastoma, and childhood leukemia. The studies are designed to test new treatment combinations, improve cancer control, and evaluate whether outcomes can be strengthened in difficult-to-treat disease.

• Testing new therapies for advanced and metastatic cancers
• Evaluating treatment effectiveness in pediatric and adult oncology
• Exploring improved approaches for leukemia and neuroblastoma

This reflects a broad oncology program with both adult and pediatric focus, supported by the department of Hematology, Oncology, Stem Cell Transplantation, and Tumor Immunology.

Research here includes trials in acute ischemic stroke, childhood stroke, and related vascular conditions, with the goal of improving recovery and reducing the risk of recurrence. The studies also examine whether new clot-busting or anti-inflammatory strategies can help patients with incomplete reperfusion or inflammatory narrowing of blood vessels.

• Improving outcomes after acute ischemic stroke
• Studying treatment for childhood stroke and focal cerebral arteriopathy
• Assessing therapies aimed at better reperfusion and stroke prevention

The Freiburg site contributes to clinical research that connects emergency neurology with vascular medicine, addressing both adult and pediatric stroke care.

Trials in this field cover lung cancer and sudden hearing loss, alongside studies relevant to breathing problems in preterm infants. The research aims to assess new treatments that may improve hearing recovery, support lung health, and strengthen respiratory outcomes early in life.

• Evaluating therapies for sudden sensorineural hearing loss
• Studying respiratory support strategies in premature infants
• Testing approaches for advanced lung cancer

These projects show a mix of oncology, ear and hearing research, and neonatal respiratory care at Universitätsklinikum Freiburg.

The site is also involved in studies on metastatic colorectal cancer and acute radiation proctitis, focusing on symptom relief and better disease control. These trials aim to improve treatment effectiveness while reducing therapy-related discomfort in patients receiving cancer care.

• Comparing treatment options for metastatic colorectal cancer
• Relieving symptoms of radiation-related rectal inflammation
• Improving quality of life during and after cancer treatment

This area highlights how clinical research at the site extends beyond tumor control to include supportive care and side-effect management.

Clinical trials in this therapeutic area focus on metastatic hormone-sensitive prostate cancer and prostate carcinoma with treatment-related bowel complications. The main purpose is to determine whether adding new therapies to standard care can improve survival, disease outcomes, and symptom control.

• Testing strategies to improve outcomes in metastatic prostate cancer
• Addressing treatment-related rectal symptoms in prostate cancer care
• Evaluating ways to strengthen standard treatment approaches

These studies reflect an ongoing effort to refine cancer care for men at Universitätsklinikum Freiburg.

Some trials at the site span multiple disease areas and focus on broader questions in treatment safety, tolerability, and overall effectiveness. They include research in advanced cancers and other complex conditions where new combinations or supportive approaches are being assessed.

• Evaluating new treatment combinations across advanced diseases
• Assessing safety and tolerability of emerging therapies
• Exploring whether added treatments can improve patient outcomes

This mixed portfolio shows the site’s wide clinical research scope across oncology, neurology, pediatrics, and supportive care.